Dr. Jonathan Sackier, Cavendish Board Member and Chief Medical Officer
Dr. Jonathan Sackier, Cavendish Chief Medical Officer is credited with helping to develop medical technologies including laparoscopic surgery, amniotic stem cells and the first commercial surgical robot, AESOP; brought to market by Computer Motion and which was then incorporated into Intuitive Surgical's immensely successful Da - Vinci robotic surgery system (NASDAQ ISRG).
has advised leading family office owned and publicly listed multi-national companies in the pharmaceutical, device and diagnostic sectors (including Karl Storz, Applied Medical, Pall Medical, Merck, Novartis and Pfizer) on technology development and many aspects of healthcare.
trained as a surgeon in London, England and built a thriving acedemic and private practice in Los Angeles, CA.
is an accomplished entrepreneur, business builder, investor and advisor to emerging and established life science companies in the United States, Europe and Australasia.
speaks internationally to lay and professional audiences on technology development & transfer and many aspects of healthcare, loves teaching & has published extensively (7 books, over 120 articles) and served multiple hospital and medical society leadership roles.
He is a frequent commentator in the media (television, radio and print in USA, Europe and Australasia).
Dr. Sackier is a member of the Board of Directors of Charlottesville, VA based Hemoshear, Inc.
Additional directorships held by Dr. Sackier include Clinvue and Rex Bionics and he acts as Medical Counsel to the Aircraft Owners and Pilots Association, AOPA.
He has served the Board of the American College of Surgeons Foundation, the Larry King Cardiac Foundation, First Star and Steppenwolf and was previously Chairman of Adenosine Therapeutics and founded and funded the Washington Institute of Surgical Endoscopy
Dr. Sackier is a frequent speaker at scientific and industry events and is a member of several leading medical societies.
has an extensive network of senior level relationships within the delivery of healthcare and business of medicine sectors.